EP4284351A1 - Composition for the treatment of painful and/or inflammatory states - Google Patents

Composition for the treatment of painful and/or inflammatory states

Info

Publication number
EP4284351A1
EP4284351A1 EP22705910.2A EP22705910A EP4284351A1 EP 4284351 A1 EP4284351 A1 EP 4284351A1 EP 22705910 A EP22705910 A EP 22705910A EP 4284351 A1 EP4284351 A1 EP 4284351A1
Authority
EP
European Patent Office
Prior art keywords
composition
cbd
substances
pain
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22705910.2A
Other languages
German (de)
French (fr)
Inventor
Antonio SCIALPI
Claudio Sebastiano Gardana
Elena PAFUNDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Specchiasol Srl
Original Assignee
Specchiasol Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Specchiasol Srl filed Critical Specchiasol Srl
Publication of EP4284351A1 publication Critical patent/EP4284351A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
    • A61K36/268—Asarum (wild ginger)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • Embodiments described here concern a composition based on cannabidiol (CBD), in particular for the therapeutic treatment of painful and/or inflammatory states. More specifically, the embodiments described here concern a composition comprising a synergistic combination of CBD or an extract containing CBD and one or more natural ingredients that help the pain relief and/or anti-inflammatory activity.
  • CBD cannabidiol
  • the composition described here can be formulated, for example, as a pharmaceutical composition or as a food supplement composition.
  • pharmacological agents generally used to treat the different types of painful states are many and include, for example, opiates, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants and ketamine.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • anticonvulsants anticonvulsants
  • antidepressants antidepressants
  • ketamine the negative side effects of these drugs limit their therapeutic dosage, and in the final analysis reduce their therapeutic efficacy.
  • Document EP- A- 1.542.657 describes a liquid formulation of cannabinoid for administration via the mucosa, in particular by spraying.
  • one purpose of the present invention is to provide a composition in particular for the therapeutic treatment of painful and/or inflammatory states which prevents the side effects typical of synthetic painkillers.
  • the Applicant has devised, tested and embodied the present invention to overcome the shortcomings of the state of the art and to obtain these and other purposes and advantages.
  • the embodiments concern a composition comprising a synergistic combination of Cannabidiol (CBD), or an extract containing CBD, with one or more substances or molecules, and/or respective natural dry extracts, with pain-relieving and/or anti-inflammatory activity.
  • CBD Cannabidiol
  • CBD therapeutic action of CBD increases if associated with other molecules and/or natural extracts with pain- relieving and/or anti-inflammatory activity.
  • various associations provided here were found to be more effective against pain and inflammatory situations than the action of the individual functional principles.
  • the composition described here is a pharmaceutical composition.
  • the pharmaceutical composition also comprises one or more pharmaceutically acceptable excipients.
  • the composition described here is a food supplement.
  • the composition described here also comprises dry extracts, coenzymes or a combination thereof.
  • composition described here is free of terpenes.
  • the natural pain-relieving, antiinflammatory agents and the respective dry extracts present in the composition described here are selected from Palmitoylethanolamide (PEA) and/or L- acetylcamitine (LAC) and/or Boswellic acids from Boswellia serrata and/or Lipoic acid and/or furanodienes from Chommiphora myrrha and/or harpagoside from Harphagophytum Procumbens, and/or gingerols and shogaols from ginger and/or curcumin or a combination thereof.
  • PDA Palmitoylethanolamide
  • LAC L- acetylcamitine
  • Boswellic acids from Boswellia serrata and/or Lipoic acid and/or furanodienes from Chommiphora myrrha and/or harpagoside from Harphagophytum Procumbens
  • gingerols and shogaols from ginger and/or curcumin or
  • the composition as above comprises CBD and at least two natural pain-relieving and/or anti-inflammatory substances.
  • One of these two substances can for example be PEA and the other can be, for example, a plant-derived anti-inflammatory substance.
  • the composition as above comprises CBD and Palmitoylethanolamide (PEA), wherein the weight ratio of PEA:CBD in said composition is from 5:1 to 1:1, in particular from 3:1 to 1:1, more in particular from 2:1 to 1:1.
  • PDA Palmitoylethanolamide
  • An example of implementation can be 1 : 1.
  • composition as above comprises CBD, Palmitoylethanolamide (PEA) and one or more plant-derived anti-inflammatory substances.
  • PDA Palmitoylethanolamide
  • the plant-derived anti-inflammatory substances can be selected from gingerols and shogaols from ginger Zingiber officinale), curcumin from Curcuma longa, harpagoside from Harphagophytum Procumbens.
  • plant-derived anti-inflammatory substances can be standardized plant extracts.
  • the composition as above comprises CBD and PEA and is free of other plant-derived anti-inflammatory and/or pain- relieving substances and/or other active principles or substances, such composition possibly including suitable and pharmaceutically acceptable excipients.
  • the weight ratio of PEA:CBD in such composition is from 5:1 to 1 :1, in particular from 3:1 to 1:1, more in particular from 2:1 to 1 : 1.
  • An example of implementation can be 1:1.
  • composition that provides the association of the substances described above can be made in the form of powder, for example single- or multi-layer tablets, single- or multi-layer tablets with differentiated release, soluble sachets, hard gelatin capsules or softgels or any other form suitable for oral intake.
  • composition according to the embodiments described here can be made available, as well as in powder form, also in liquid form.
  • the liquid form can be made in the form of simple syrups, emulsified syrups, suspensions or preparations for extemporaneous use.
  • the present description also includes the intervals that derive from uniting or overlapping two or more intervals described, unless otherwise indicated.
  • the present description also includes the intervals that can derive from the combination of two or more values taken at different points, unless otherwise indicated.
  • CBD is a cannabinoid found in Cannabis sativa.
  • cannabinoid refers to compounds that activate G-protein coupled to cannabinoid receptors 1 and 2 (CB1 and CB2).
  • CB1 receptors located mainly on the neurons of the hippocampus and basal ganglia, mediate the psychoactive actions of cannabinoids.
  • CB2 receptors are found mainly on tissues and circulating cells of the immune system.
  • CBD Unlike the psychoactive constituent Tetrahydrocannabinol (THC), CBD does not exhibit psychoactive activity because it has no direct effect on CB1 and CB2 receptors, but it modulates the effect of the agonists, suggesting an allosteric function. Furthermore, CBD binds to PPARy, GPR3/6/12/18/55, TRPV1/2, TRPA1, to the 5-hydroxytryptamine receptor and to mitochondrial proteins. Furthermore, CBD is well tolerated even when administered in high concentrations and the therapeutic benefits it brings in the treatment of childhood epilepsy are well documented. On the contrary, until now its effects on inflammation have been mainly studied on animal models.
  • CBD fatty acid amide hydrolase
  • CBD also counteracts THC-induced psychoactivity, sedation and tachycardia.
  • CBD comes with a long list of medical properties.
  • the main one among these is the ability to relieve the symptoms of various ailments, such as chronic pain, inflammation, migraines, arthritis, spasms, epilepsy and schizophrenia.
  • CBD has some anti-cancer properties, and new uses and applications are constantly being discovered thanks to medical research.
  • the Applicant has found for the first time that the association of CBD with one or more natural ingredients or substances that act as agents with pain- relieving and/or anti-inflammatory properties, in particular molecules, and/or respective natural pain-relieving and/or anti-inflammatory dry extracts, more in particular one or more pain-relieving and anti-inflammatory substances present in nature, results in a synergistic combination between CBD and the above natural ingredients or substances that act as agents with pain-relieving and/or antiinflammatory properties.
  • This synergistic combination is particularly effective for therapeutic treatment, in particular of painful and/or inflammatory states.
  • the embodiments described here therefore provide a safe composition of CBD or a CBD-containing extract with one or more molecules and/or natural extracts with pain-relieving and/or anti-inflammatory properties, such composition exhibiting ameliorative and synergistic effects in therapeutic treatment, in particular of painful or inflammatory states, compared to CBD alone.
  • the composition described here comprises CBD from 5 to 90% w/w of the composition.
  • the composition described here comprises the one or more natural pain-relieving and/or anti-inflammatory substances as above from 0.5 to 90% w/w of the composition.
  • composition described here can be for human or veterinary use.
  • composition described here can be, in particular, a pharmaceutical composition.
  • composition as above can be provided or used in both powder and also liquid form.
  • the composition described here comprises CBD in liquid or solid form, wherein the quantity of CBD in the composition is from 5 to 1000 mg per unit dose.
  • the one or more natural pain-relieving and/or antiinflammatory substances as above are one or more selected from Palmitoylethanolamide (PEA) or L-acetylcamitine (LAC) and/or Boswellic acids from Boswellia serrata and/or Lipoic acid and/or a mixture of antioxidant substances extracted mainly from the bark of Maritime Pine (Pinus pinaster) and/or from the seeds of Vitis vinifera (for example Pycnogenol) and/or furanodienes from Chommiphora myrrha, or extract of Chommiphora myrrha as a source of furanodienes and/or harpagoside from Harphagophytum Procumbens, and/or gingerols and shogaols from ginger and/or curcumin from Curcuma longa, or a combination thereof.
  • the quantity of the natural pain-relieving and/or anti-inflammatory substances as above in the composition described here is from Palmitoylethanolamide
  • the composition described here comprises CBD and PEA.
  • composition described here is free of terpenes.
  • the composition as above comprises CBD and Palmitoylethanolamide (PEA), wherein the weight ratio of PEA:CBD in such composition is from 5:1 to 1:1, in particular from 3:1 to 1:1, more in particular from 2: 1 to 1 : 1.
  • PDA Palmitoylethanolamide
  • An example of implementation can be 1:1.
  • composition as above comprises CBD, Palmitoylethanolamide (PEA) and one or more plant-derived anti-inflammatory substances.
  • PDA Palmitoylethanolamide
  • such plant-derived anti-inflammatory substances are selected from gingerols and shogaols from ginger (Zingiber officinale , curcumin from Curcuma longa, harpagoside from Harphagophytum Procumbens.
  • plant-derived anti-inflammatory substances are standardized plant extracts.
  • composition described here comprises CBD, PEA and titrated dry extract of Commiphora myrrha.
  • composition described here comprises CBD, PEA and curcumin or an extract containing curcumin.
  • composition described here comprises CBD, titrated dry extract of Boswellia s errata and LAC.
  • composition described here comprises CBD and Lipoic acid.
  • the composition described here comprises CBD and a mixture of antioxidant substances extracted mainly from the bark of Maritime Pine (Pinus pinaster) and/or from the seeds of Vitis vinifera (for example Pycnogenol).
  • composition described here comprises CBD, PEA and ginger or an extract containing ginger.
  • composition described here comprises CBD, PEA and Harphagophytum Procumbens or an extract containing harpagoside from Harphagophytum Procumbens.
  • composition described here comprises CBD and LAC.
  • composition described here comprises CBD, PEA and LAC.
  • the composition described here can include one or more compounds with antioxidant activity, for example selected from a mixture of antioxidant substances extracted mainly from the bark of maritime pine Pinus pinaster) and/or from the seeds of Vitis vinifera (for example Pycnogenol), Lipoic acid, n-Acetyl cysteine, Polyphenols, Resveratrol, Polydatin, Quercetin, Rutin, Luteolin, or a combination thereof.
  • Such one or more compounds with antioxidant activity can for example be present between 5 and 60% w/w of the composition.
  • both the mixture of antioxidants extracted from Pinus pinaster and/or from Vitis vinifera (for example Pycnogenol) and also Lipoic acid are strong antioxidants that also have pain-relieving and/or anti-inflammatory properties and therefore can act as natural pain-relieving and/or antiinflammatory substances in the composition in accordance with the present description.
  • the composition described here can include CBD together with the mixture of antioxidants extracted from Pinus pinaster and/or from Vitis vinifera (for example Pycnogenol) and/or Lipoic acid.
  • composition described here can be made or supplied in the form of single- or multi-layer tablets, capsules, softgels, granules, powder, sachets, suspensions, solutions, formulations with modified release, double chamber sachets, topical formulations such as creams, ointments, emulsions and dispersions.
  • composition described here can comprise suitable and pharmaceutically acceptable excipients, such as diluents, disintegrants, binders, solubilizing agents, lubricants, sliding agents, solvents, desiccants, etc., or a combination thereof.
  • suitable and pharmaceutically acceptable excipients such as diluents, disintegrants, binders, solubilizing agents, lubricants, sliding agents, solvents, desiccants, etc., or a combination thereof.
  • the composition described here can comprise, in addition or as a replacement, further additives and/or excipients of pharmaceutical or food grade, that is, substances without therapeutic activity suitable for pharmaceutical or food use.
  • the ingredients acceptable for pharmaceutical or food use comprise all the auxiliary substances known to the person of skill in the art such as, as a nonlimiting example, diluents, solvents, solubilizers, thickeners, sweeteners, flavorings, dyes, lubricants, surfactants, antimicrobials, antioxidants, preservatives, buffers to stabilize the pH and mixtures thereof.
  • the excipients can be in powder form.
  • powdered excipients are selected from microcrystalline cellulose, lactose, starch, silica, ammonium alginate, calcium carbonate, calcium lactate, di- or tri-basic calcium phosphate, calcium silicate, calcium sulphate, com starch, pregelatinized starch, erythritol, ethyl cellulose, fructose, glyceryl palmitostearate, isomalt, kaolin, sugar alcohols, lactitol, magnesium carbonate, magnesium oxide, maltose, mannitol, medium chain triglycerides, sodium alginate, sodium chloride, sorbitol, P-cyclodextrins, talc, trehalose.
  • the quantity of excipient in the composition described here can, for example, be from 5 to 50% w/w of the composition.
  • the excipients can be liquid.
  • such liquid excipients act as a solvent of the substances present, that is, the CBD and the natural substances with pain-relieving and/or anti-inflammatory properties, for example PEA and the plant-derived anti-inflammatory substances described above.
  • Such liquid excipients can for example be selected from water, ethyl alcohol, isopropyl alcohol, propylene glycol, almond oil, benzyl alcohol, benzyl benzoate, butylene glycol, carbon dioxide, castor oil, com oil, cottonseed oil, dimethyl ether, albumin, dimethyl phthalate, dimethyl sulfoxide, dimethylacetamide, ethyl acetate, ethyl lactate, ethyl oleate, glycerin, glycofurol, isopropyl myristate, isopropyl palmitate, light mineral oil, medium chain triglycerides, methyl lactate, mineral oil, monoethanolamine, olive oil, peanut oil, polyethylene glycol, poly oxy 1 35 castor oil, propylene carbonate, pyrrolidone, safflower oil, sesame oil, soybean oil, sunflower oil, triacetin, tricaprilin, triethanolamine, triethyl
  • compositions in accordance with the embodiments described here are described below.
  • CBD Cannabidiol
  • PEA 0.5-90% (w/w)
  • CBD Cannabidiol
  • PEA 0.5-90% (w/w)
  • CBD Cannabidiol
  • PEA 0.5-90% (w/w)
  • Curcumin or extract containing curcumin 1-90% (w/w)
  • CBD Cannabidiol
  • CBD Cannabidiol
  • Lipoic Acid 0.5-90% (w/w)
  • CBD Cannabidiol
  • CBD Cannabidiol
  • PEA 0.5-90% (w/w)
  • Gingerols and shogaols from ginger (Zingiber officinale), dry extract: 1-90% (w/w)
  • CBD Cannabidiol
  • PEA 0.5-90% (w/w)
  • compositions of the examples described above could include suitable excipients, as described above.
  • the Applicant carried out a study to verify the synergistic action of a formulation containing CBD and PEA in reducing the levels of some pro- inflammatory cytokines in an in vitro model consisting of human leukocytes.
  • IFN-y Interferon y
  • TNF-a Tumor Necrosis Factor a
  • IL-6 interleukin-6
  • Table 1 Effect of the different treatments on the production of IL-6 caused by inflammation induced by TNF-a in human leukocyte cells.
  • Results are the mean of 3 wells in triplicate ⁇ S.D. The values with different letters within the same column in Table 1 are significantly different (P ⁇ 0.05).
  • CBD+PEA association in particular at low concentrations (in the example provided 5pM), has significantly suppressed the release of the pro-inflammatory cytokine, IL-6, induced by TNF-a, in significantly greater quantities than single treatments with CBD and PEA, demonstrating the presence of a synergistic effect.
  • This datum is particularly important for the formulation of CBD+PEA based products used as anti-inflammatories.
  • the Applicant carried out a study to verify the synergistic action of a formulation containing CBD, PEA and a Standardized Plant Extract (SPE) in reducing the levels of some pro-inflammatory cytokines in an in vitro model consisting of human leukocytes.
  • the plant extracts evaluated were: Curcuma longa - standardized in curcumin
  • IFN-y Interferon y
  • TNF-a Tumor Necrosis Factor a
  • Table 2 Effect of CBD on the production of IL-6 caused by inflammation induced by TNF-a in human leukocyte cells.
  • Results are the mean of 3 wells in triplicate ⁇ S.D. The values with different letters within the same column are significantly different (P ⁇ 0.05).
  • CBD+PEA at low concentrations, significantly suppressed the release of the pro-inflammatory cytokine, IL-6, induced by TNF-a, in significantly greater quantities than single treatments with CBD and PEA.
  • some dry plant extracts such as those mentioned above, in association with CBD and PEA, increase the anti-inflammatory effect of the preparation. This datum will be particularly important for the formulation of CBD+PEA+ SPV based products used as anti-inflammatories and/or pain relievers.

Abstract

Composition comprising Cannabidiol (CBD) and one or more natural pain-relieving and/or anti-inflammatory substances, said substances comprising palmitoylethanolamide (PEA), in particular for the therapeutic treatment of painful and/or inflammatory states.

Description

“COMPOSITION FOR THE TREATMENT OF PAINFUL AND/OR INFLAMMATORY STATES”
FIELD OF THE INVENTION
Embodiments described here concern a composition based on cannabidiol (CBD), in particular for the therapeutic treatment of painful and/or inflammatory states. More specifically, the embodiments described here concern a composition comprising a synergistic combination of CBD or an extract containing CBD and one or more natural ingredients that help the pain relief and/or anti-inflammatory activity. The composition described here can be formulated, for example, as a pharmaceutical composition or as a food supplement composition.
BACKGROUND OF THE INVENTION
It is known that humans and animals suffering from chronic and severe pain require good clinical management. The pharmacological agents generally used to treat the different types of painful states are many and include, for example, opiates, non-steroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants and ketamine. However, the negative side effects of these drugs limit their therapeutic dosage, and in the final analysis reduce their therapeutic efficacy.
In recent years there have been considerable improvements in the understanding of the pathophysiological mechanisms that underlie the manifestations of chronic pain and various other molecules have been tested that have been found to be effective in treating pain and free from unwanted side effects.
Document US-A-2021/015774 describes a tablet or composition comprising N-acyl ethanolamine or PEA, a cannabinoid and a terpene.
Document EP- A- 1.542.657 describes a liquid formulation of cannabinoid for administration via the mucosa, in particular by spraying.
There is therefore a need to provide a composition for the therapeutic treatment, in particular of painful and/or inflammatory states, which overcomes one or more of the disadvantages of the state of the art.
In particular, one purpose of the present invention is to provide a composition in particular for the therapeutic treatment of painful and/or inflammatory states which prevents the side effects typical of synthetic painkillers.
The Applicant has devised, tested and embodied the present invention to overcome the shortcomings of the state of the art and to obtain these and other purposes and advantages.
SUMMARY OF THE INVENTION
The present invention is set forth and characterized in the independent claim. The dependent claims describe other characteristics of the present invention or variants to the main inventive idea.
In accordance with the above purposes, the embodiments concern a composition comprising a synergistic combination of Cannabidiol (CBD), or an extract containing CBD, with one or more substances or molecules, and/or respective natural dry extracts, with pain-relieving and/or anti-inflammatory activity.
The present inventors have discovered that the therapeutic action of CBD increases if associated with other molecules and/or natural extracts with pain- relieving and/or anti-inflammatory activity. In summary, the various associations provided here were found to be more effective against pain and inflammatory situations than the action of the individual functional principles.
According to some embodiments, the composition described here is a pharmaceutical composition.
According to some embodiments, the pharmaceutical composition also comprises one or more pharmaceutically acceptable excipients.
According to other embodiments, the composition described here is a food supplement.
According to other embodiments, the composition described here also comprises dry extracts, coenzymes or a combination thereof.
According to other embodiments, the composition described here is free of terpenes.
In accordance with still other embodiments, the natural pain-relieving, antiinflammatory agents and the respective dry extracts present in the composition described here are selected from Palmitoylethanolamide (PEA) and/or L- acetylcamitine (LAC) and/or Boswellic acids from Boswellia serrata and/or Lipoic acid and/or furanodienes from Chommiphora myrrha and/or harpagoside from Harphagophytum Procumbens, and/or gingerols and shogaols from ginger and/or curcumin or a combination thereof.
In accordance with still other embodiments, the composition as above comprises CBD and at least two natural pain-relieving and/or anti-inflammatory substances. One of these two substances can for example be PEA and the other can be, for example, a plant-derived anti-inflammatory substance.
In accordance with still other embodiments, the composition as above comprises CBD and Palmitoylethanolamide (PEA), wherein the weight ratio of PEA:CBD in said composition is from 5:1 to 1:1, in particular from 3:1 to 1:1, more in particular from 2:1 to 1:1. An example of implementation can be 1 : 1.
In accordance with still other embodiments, the composition as above comprises CBD, Palmitoylethanolamide (PEA) and one or more plant-derived anti-inflammatory substances.
In possible implementations, the plant-derived anti-inflammatory substances can be selected from gingerols and shogaols from ginger Zingiber officinale), curcumin from Curcuma longa, harpagoside from Harphagophytum Procumbens.
In other possible implementations, such plant-derived anti-inflammatory substances can be standardized plant extracts.
In accordance with other embodiments, the composition as above comprises CBD and PEA and is free of other plant-derived anti-inflammatory and/or pain- relieving substances and/or other active principles or substances, such composition possibly including suitable and pharmaceutically acceptable excipients. Also in this case, for example, the weight ratio of PEA:CBD in such composition is from 5:1 to 1 :1, in particular from 3:1 to 1:1, more in particular from 2:1 to 1 : 1. An example of implementation can be 1:1.
The composition that provides the association of the substances described above can be made in the form of powder, for example single- or multi-layer tablets, single- or multi-layer tablets with differentiated release, soluble sachets, hard gelatin capsules or softgels or any other form suitable for oral intake.
Furthermore, the composition according to the embodiments described here can be made available, as well as in powder form, also in liquid form. For example, the liquid form can be made in the form of simple syrups, emulsified syrups, suspensions or preparations for extemporaneous use.
DESCRIPTION OF SOME EMBODIMENTS
We will now refer in detail to the possible embodiments of the present invention, of which one or more examples are described below, by way of a non- limiting illustration. The phraseology and terminology used here is also for the purposes of providing non-limiting examples.
It is also understood that elements and characteristics of one embodiment can be conveniently combined or incorporated into other embodiments without further clarifications. All the percentages and ratios indicated shall be understood to refer to the weight of the total composition (w/w), unless otherwise indicated.
All the percentage intervals reported here are provided with the provision that the sum with respect to the overall composition is 100%, unless otherwise indicated. All the intervals reported here shall be understood to include the extremes, including those that report an interval “between” two values, unless otherwise indicated.
The present description also includes the intervals that derive from uniting or overlapping two or more intervals described, unless otherwise indicated. The present description also includes the intervals that can derive from the combination of two or more values taken at different points, unless otherwise indicated.
The embodiments described here concern a composition comprising Cannabidiol (CBD) or an extract containing CBD. CBD is a cannabinoid found in Cannabis sativa. The term cannabinoid refers to compounds that activate G-protein coupled to cannabinoid receptors 1 and 2 (CB1 and CB2). CB1 receptors, located mainly on the neurons of the hippocampus and basal ganglia, mediate the psychoactive actions of cannabinoids. CB2 receptors are found mainly on tissues and circulating cells of the immune system. Unlike the psychoactive constituent Tetrahydrocannabinol (THC), CBD does not exhibit psychoactive activity because it has no direct effect on CB1 and CB2 receptors, but it modulates the effect of the agonists, suggesting an allosteric function. Furthermore, CBD binds to PPARy, GPR3/6/12/18/55, TRPV1/2, TRPA1, to the 5-hydroxytryptamine receptor and to mitochondrial proteins. Furthermore, CBD is well tolerated even when administered in high concentrations and the therapeutic benefits it brings in the treatment of childhood epilepsy are well documented. On the contrary, until now its effects on inflammation have been mainly studied on animal models. Studies on rodents with osteoarthritis or collagen-induced arthritis have demonstrated the antiinflammatory and analgesic effects of CBD, but, to date, these studies have not yet clarified the mechanism of action. Several studies report that CBD reduces the production of pro-inflammatory cytokines, such as TNF-a, IL-6, IL- 10, and induces the reduction of fatty acid amide hydrolase (FAAH) activity, thus increasing the production of Anandamide, an anti-inflammatory endocannabinoid.
Furthermore, and just as importantly, CBD also counteracts THC-induced psychoactivity, sedation and tachycardia.
In summary, CBD comes with a long list of medical properties. The main one among these is the ability to relieve the symptoms of various ailments, such as chronic pain, inflammation, migraines, arthritis, spasms, epilepsy and schizophrenia. Furthermore, it has been proven that CBD has some anti-cancer properties, and new uses and applications are constantly being discovered thanks to medical research.
The Applicant has found for the first time that the association of CBD with one or more natural ingredients or substances that act as agents with pain- relieving and/or anti-inflammatory properties, in particular molecules, and/or respective natural pain-relieving and/or anti-inflammatory dry extracts, more in particular one or more pain-relieving and anti-inflammatory substances present in nature, results in a synergistic combination between CBD and the above natural ingredients or substances that act as agents with pain-relieving and/or antiinflammatory properties. The Applicant has found that this synergistic combination is particularly effective for therapeutic treatment, in particular of painful and/or inflammatory states.
The embodiments described here therefore provide a safe composition of CBD or a CBD-containing extract with one or more molecules and/or natural extracts with pain-relieving and/or anti-inflammatory properties, such composition exhibiting ameliorative and synergistic effects in therapeutic treatment, in particular of painful or inflammatory states, compared to CBD alone.
In some embodiments, the composition described here comprises CBD from 5 to 90% w/w of the composition.
In some embodiments, the composition described here comprises the one or more natural pain-relieving and/or anti-inflammatory substances as above from 0.5 to 90% w/w of the composition.
The composition described here can be for human or veterinary use.
In some embodiments, the composition described here can be, in particular, a pharmaceutical composition.
In some embodiments, the composition as above can be provided or used in both powder and also liquid form.
In some embodiments, the composition described here comprises CBD in liquid or solid form, wherein the quantity of CBD in the composition is from 5 to 1000 mg per unit dose.
In some embodiments, the one or more natural pain-relieving and/or antiinflammatory substances as above are one or more selected from Palmitoylethanolamide (PEA) or L-acetylcamitine (LAC) and/or Boswellic acids from Boswellia serrata and/or Lipoic acid and/or a mixture of antioxidant substances extracted mainly from the bark of Maritime Pine (Pinus pinaster) and/or from the seeds of Vitis vinifera (for example Pycnogenol) and/or furanodienes from Chommiphora myrrha, or extract of Chommiphora myrrha as a source of furanodienes and/or harpagoside from Harphagophytum Procumbens, and/or gingerols and shogaols from ginger and/or curcumin from Curcuma longa, or a combination thereof. In possible embodiments, the quantity of the natural pain-relieving and/or anti-inflammatory substances as above in the composition described here is from 2 to 2000 mg per unit dose.
According to one possible embodiment, the composition described here comprises CBD and PEA.
According to other embodiments, the composition described here is free of terpenes.
In accordance with still other embodiments, which can be combined with all the embodiments described here, the composition as above comprises CBD and Palmitoylethanolamide (PEA), wherein the weight ratio of PEA:CBD in such composition is from 5:1 to 1:1, in particular from 3:1 to 1:1, more in particular from 2: 1 to 1 : 1. An example of implementation can be 1:1.
In accordance with still other embodiments, which can be combined with all the embodiments described here, the composition as above comprises CBD, Palmitoylethanolamide (PEA) and one or more plant-derived anti-inflammatory substances.
In some embodiments, which can be combined with all the embodiments described here, such plant-derived anti-inflammatory substances are selected from gingerols and shogaols from ginger (Zingiber officinale , curcumin from Curcuma longa, harpagoside from Harphagophytum Procumbens.
In other embodiments, which can be combined with all the embodiments described here, such plant-derived anti-inflammatory substances are standardized plant extracts.
According to another possible embodiment, which can be combined with all the embodiments described here, the composition described here comprises CBD, PEA and titrated dry extract of Commiphora myrrha.
In accordance with another possible embodiment, which can be combined with all the embodiments described here, the composition described here comprises CBD, PEA and curcumin or an extract containing curcumin.
In accordance with another possible embodiment, which can be combined with all the embodiments described here, the composition described here comprises CBD, titrated dry extract of Boswellia s errata and LAC.
According to another possible embodiment, which can be combined with all the embodiments described here, the composition described here comprises CBD and Lipoic acid.
According to a possible embodiment, which can be combined with all the embodiments described here, the composition described here comprises CBD and a mixture of antioxidant substances extracted mainly from the bark of Maritime Pine (Pinus pinaster) and/or from the seeds of Vitis vinifera (for example Pycnogenol).
In accordance with another possible embodiment, which can be combined with all the embodiments described here, the composition described here comprises CBD, PEA and ginger or an extract containing ginger.
In accordance with another possible embodiment, which can be combined with all the embodiments described here, the composition described here comprises CBD, PEA and Harphagophytum Procumbens or an extract containing harpagoside from Harphagophytum Procumbens.
In accordance with still another possible embodiment, which can be combined with all the embodiments described here, the composition described here comprises CBD and LAC.
According to another possible embodiment, which can be combined with all the embodiments described here, the composition described here comprises CBD, PEA and LAC.
According to another possible embodiment, which can be combined with all the embodiments described here, the composition described here can include one or more compounds with antioxidant activity, for example selected from a mixture of antioxidant substances extracted mainly from the bark of maritime pine Pinus pinaster) and/or from the seeds of Vitis vinifera (for example Pycnogenol), Lipoic acid, n-Acetyl cysteine, Polyphenols, Resveratrol, Polydatin, Quercetin, Rutin, Luteolin, or a combination thereof. Such one or more compounds with antioxidant activity can for example be present between 5 and 60% w/w of the composition.
In particular, both the mixture of antioxidants extracted from Pinus pinaster and/or from Vitis vinifera (for example Pycnogenol) and also Lipoic acid are strong antioxidants that also have pain-relieving and/or anti-inflammatory properties and therefore can act as natural pain-relieving and/or antiinflammatory substances in the composition in accordance with the present description. Accordingly, as indicated above, in some embodiments the composition described here can include CBD together with the mixture of antioxidants extracted from Pinus pinaster and/or from Vitis vinifera (for example Pycnogenol) and/or Lipoic acid.
In some embodiments, which can be combined with all the embodiments described here, the composition described here can be made or supplied in the form of single- or multi-layer tablets, capsules, softgels, granules, powder, sachets, suspensions, solutions, formulations with modified release, double chamber sachets, topical formulations such as creams, ointments, emulsions and dispersions.
In some embodiments, which can be combined with all of the embodiments described here, the composition described here can comprise suitable and pharmaceutically acceptable excipients, such as diluents, disintegrants, binders, solubilizing agents, lubricants, sliding agents, solvents, desiccants, etc., or a combination thereof.
In some embodiments, the composition described here can comprise, in addition or as a replacement, further additives and/or excipients of pharmaceutical or food grade, that is, substances without therapeutic activity suitable for pharmaceutical or food use. In the context of the present description, the ingredients acceptable for pharmaceutical or food use comprise all the auxiliary substances known to the person of skill in the art such as, as a nonlimiting example, diluents, solvents, solubilizers, thickeners, sweeteners, flavorings, dyes, lubricants, surfactants, antimicrobials, antioxidants, preservatives, buffers to stabilize the pH and mixtures thereof.
In some embodiments, the excipients can be in powder form. Examples of powdered excipients are selected from microcrystalline cellulose, lactose, starch, silica, ammonium alginate, calcium carbonate, calcium lactate, di- or tri-basic calcium phosphate, calcium silicate, calcium sulphate, com starch, pregelatinized starch, erythritol, ethyl cellulose, fructose, glyceryl palmitostearate, isomalt, kaolin, sugar alcohols, lactitol, magnesium carbonate, magnesium oxide, maltose, mannitol, medium chain triglycerides, sodium alginate, sodium chloride, sorbitol, P-cyclodextrins, talc, trehalose. The quantity of excipient in the composition described here can, for example, be from 5 to 50% w/w of the composition.
In the embodiments in which the composition described here can be in liquid form, the excipients can be liquid. Favorably, such liquid excipients act as a solvent of the substances present, that is, the CBD and the natural substances with pain-relieving and/or anti-inflammatory properties, for example PEA and the plant-derived anti-inflammatory substances described above. Such liquid excipients can for example be selected from water, ethyl alcohol, isopropyl alcohol, propylene glycol, almond oil, benzyl alcohol, benzyl benzoate, butylene glycol, carbon dioxide, castor oil, com oil, cottonseed oil, dimethyl ether, albumin, dimethyl phthalate, dimethyl sulfoxide, dimethylacetamide, ethyl acetate, ethyl lactate, ethyl oleate, glycerin, glycofurol, isopropyl myristate, isopropyl palmitate, light mineral oil, medium chain triglycerides, methyl lactate, mineral oil, monoethanolamine, olive oil, peanut oil, polyethylene glycol, poly oxy 1 35 castor oil, propylene carbonate, pyrrolidone, safflower oil, sesame oil, soybean oil, sunflower oil, triacetin, tricaprilin, triethanolamine, triethyl citrate, triolein, water-miscible solvents or suchlike. The quantity of liquid excipient used in the composition described here is typically the quantity required to make the composition in liquid form.
The composition in accordance with the embodiments described here can be used for the therapeutic treatment of one or more of the following forms of pain:
- somatic pain
- visceral pain
- non-nociceptive pain
- neuropathic pain
- sympathetic pain.
EXAMPLES
Some examples of compositions in accordance with the embodiments described here are described below.
Example of composition 1
Cannabidiol (CBD): 5-90% (w/w)
PEA: 0.5-90% (w/w)
Example of composition 2
Cannabidiol (CBD): 5-90% (w/w)
PEA: 0.5-90% (w/w)
Titrated dry extract of Commiphora myrra: 0.5-90% (w/w)
Example of composition 3
Cannabidiol (CBD): 5-90% (w/w)
PEA: 0.5-90% (w/w)
Curcumin or extract containing curcumin: 1-90% (w/w)
Example of composition 4
Cannabidiol (CBD): 5-90% (w/w) Titrated dry extract of Boswellia serrata 0.5-90% (w/w)
L- Acetyl Carnitine: 1-90% (w/w)
Example of composition 5
Cannabidiol (CBD): 5-90% (w/w)
L-Acetyl Carnitine: 0.5-90% (w/w)
Example of composition 6
Cannabidiol (CBD): 5-90% (w/w)
Lipoic Acid: 0.5-90% (w/w)
Example of composition 7
Cannabidiol (CBD): 5-90% (w/w)
Pycnogenol: 0.5-90% (w/w)
Example of composition 8
Cannabidiol (CBD): 5-90% (w/w)
PEA: 0.5-90% (w/w)
Gingerols and shogaols from ginger (Zingiber officinale), dry extract: 1-90% (w/w)
Example of composition 9
Cannabidiol (CBD): 5-90% (w/w)
PEA: 0.5-90% (w/w)
Harpagoside from Harphagophytum Procumbens, dry extract: 1-90% (w/w)
It is understood that, depending on the applications, intended use or physical forms provided, the compositions of the examples described above could include suitable excipients, as described above.
CBD and PEA EXPERIMENTAL TRIALS
The Applicant carried out a study to verify the synergistic action of a formulation containing CBD and PEA in reducing the levels of some pro- inflammatory cytokines in an in vitro model consisting of human leukocytes.
Cells were seeded at approximately 5><105 cells per well in 24-well polystyrene plates, into which the following treatments were pipetted (n=3):
1) carrier (buffers)
2) inflammatory protocol - IFN-y (10 ng/ml) for 8 h, followed by TNF-a (10 ng/ml) for 16 h
3) test 1 - inflammatory protocol + CBD (5pM) 4) test 2 - inflammatory protocol + PEA (5pM)
5) test 3 - inflammatory protocol + CBD + PEA (5pM)
IFN-y: Interferon y; TNF-a: Tumor Necrosis Factor a
RESULTS
To quantify the effects of CBD and its association with PEA on the inflammatory response, the concentration of interleukin-6 (IL-6) was measured, normalized for the protein content determined by means of BCA assay. The experimental conditions were mediated by tripled readings. Table 1 below summarizes the effects of the different treatments on the production of IL-6 in human leukocytes stimulated with TNF-a.
Table 1: Effect of the different treatments on the production of IL-6 caused by inflammation induced by TNF-a in human leukocyte cells.
Test IL-6
% Increase
Carrier 25+1
IFN-y + TNF-a 330+17
IFN-y + TNF-a + CBD (5 pM) 180±15a
IFN-y + TNF-a + PEA (5 pM) 175±10a
IFN-y + TNF-a + CBD + PEA (5 pM) 147+1 lb
Results are the mean of 3 wells in triplicate ± S.D. The values with different letters within the same column in Table 1 are significantly different (P <0.05).
Based on the data reported above in Table 1, it can be deduced that the CBD+PEA association, in particular at low concentrations (in the example provided 5pM), has significantly suppressed the release of the pro-inflammatory cytokine, IL-6, induced by TNF-a, in significantly greater quantities than single treatments with CBD and PEA, demonstrating the presence of a synergistic effect. This datum is particularly important for the formulation of CBD+PEA based products used as anti-inflammatories.
Although the embodiments of the composition have been described and shown here with reference to some of its uses and to various associations with the indicated components mentioned above, the person of skill in the art will appreciate that it is possible to make different adaptations, changes, modifications, substitutions, deletions or additions of components, procedures and protocols without departing from the spirit and scope of the invention. For example, dosages other than those indicated can in particular be applicable as a consequence of variations in the response of the treated subject for any of the indications listed above. The specific pharmacological responses observed may vary depending on the particular active compounds selected along with the pharmaceutical carriers mentioned. Furthermore, responses may vary depending on the type of formulation and mode of administration employed, and such expected variations or differences in results are contemplated in accordance with the purposes and practices of the present invention.
CBD, PEA AND PLANT EXTRACT EXPERIMENTAL TESTS
The Applicant carried out a study to verify the synergistic action of a formulation containing CBD, PEA and a Standardized Plant Extract (SPE) in reducing the levels of some pro-inflammatory cytokines in an in vitro model consisting of human leukocytes. The plant extracts evaluated were: Curcuma longa - standardized in curcumin
Harpagophytum Procumbens - standardized in harpagoside Zingiber officinale - standardized in gingerols and shogaols
Cells were seeded at approximately 5><105 cells per well in 24- well polystyrene plates, into which the following treatments were pipetted (n=3):
1) carrier (buffers)
2) inflammatory protocol - IFN-y (10 ng/ml) for 8 h, followed by TNF-a (10 ng/ml) for 16 h
3) test 1 - inflammatory protocol + CBD (5 pM)
4) test 2 - inflammatory protocol + PEA (5 pM)
5) test 3 - inflammatory protocol + CBD + PEA (5 pM, 1:1)
6) test 3 - inflammatory protocol + CBD + PEA + Standardized extract (5 pM, 1:1:1)
IFN-y, Interferon y; TNF-a, Tumor Necrosis Factor a
RESULTS To quantify the effects of CBD, PEA and SPV on the inflammatory response, the concentration of interleukin-6 (IL-6) was measured, normalized for the protein content determined by means of BCA assay. The experimental conditions were mediated by tripled readings. Table 2 below summarizes the effects of the different treatments on the production of IL- 6 in human leukocytes stimulated with TNF-a.
Table 2: Effect of CBD on the production of IL-6 caused by inflammation induced by TNF-a in human leukocyte cells.
Test IL-6
% Increase
Carrier 25±1
IFN-y + TNF-a 315±15
IFN-y + TNF-a + CBD (5 pM) 178± 14a
IFN-y + TNF-a + PEA (5 pM, 1 : 1 ) 172± 10a
IFN-y + TNF-a + CBD + PEA (5 pM) 151±6b
IFN-Y + TNF-a + Curcuma ES (5pM 160±7b curcumin)
IFN-Y + TNF-a + CBD + PEA + 121±12c
Curcuma ES (5pM, 1:1:1)
IFN-y + TNF-a + Harphagophytum ES 141±7b
(5 pM harpagoside)
Results are the mean of 3 wells in triplicate ± S.D. The values with different letters within the same column are significantly different (P <0.05).
From what is reported in Table 2, it can be deduced that the addition of standardized extract of Curcuma longa or Harpagophytum Procumbens or Zingiber officinale to the mixture of CBD+PEA significantly increases the antiinflammatory action of the preparation.
It is interesting to note that the Applicant found that the CBD+PEA combination, at low concentrations, significantly suppressed the release of the pro-inflammatory cytokine, IL-6, induced by TNF-a, in significantly greater quantities than single treatments with CBD and PEA. Furthermore, it has been found that some dry plant extracts, such as those mentioned above, in association with CBD and PEA, increase the anti-inflammatory effect of the preparation. This datum will be particularly important for the formulation of CBD+PEA+ SPV based products used as anti-inflammatories and/or pain relievers.
It is clear that modifications and/or additions of parts and/or steps may be made to the composition as described heretofore, without departing from the field and scope of the present invention as defined by the claims.

Claims

1. Composition comprising Cannabidiol (CBD) and one or more natural pain- relieving and/or anti-inflammatory substances, wherein said one or more natural pain-relieving and/or anti-inflammatory substances comprise Palmitoylethanolamide (PEA), wherein the weight ratio of PEA:CBD in said composition is from 5:1 to 1:1, in particular from 3:1: to 1:1, more in particular from 2:1 to 1 :1.
2. Composition as in claim 1, wherein CBD is from 5 to 90% w/w of the composition.
3. Composition as in claim 1 or 2, wherein said one or more natural pain- relieving and anti-inflammatory substances are from 0.5 to 90% w/w of the composition.
4. Composition as in claim 1, 2 or 3, wherein said one or more natural pain- relieving and anti-inflammatory substances also include one or more substances selected from L-acetylcamitine (LAC) and/or Boswellic acids from Boswellia serrata, and/or Lipoic acid and/or a mixture of antioxidant substances extracted mainly from the bark of Maritime Pine (Pinus pinaster) and/or from the seeds of Vitis vinifera and/or furanodienes from Chommiphora myrrha, and/or harpagoside of Harphagophytum Procumbens and/or gingerols and shogaols from ginger and/or curcumin or a combination thereof.
5. Composition as in any claim from 1 to 4, wherein said composition comprises CBD, Palmitoylethanolamide (PEA) and one or more plant-derived antiinflammatory substances.
6. Composition as in claim 5, wherein said plant-derived anti-inflammatory substances are selected from gingerols and shogaols from ginger, curcumin, harpagoside from Harphagophytum Procumbens.
7. Composition as in claim 6, wherein said plant-derived anti-inflammatory substances are standardized plant extracts.
8. Composition as in any claim from 1 to 7, wherein said composition is a pharmaceutical composition.
9. Composition as in claim 8, wherein said composition also comprises pharmaceutically acceptable excipients.
10. Composition as in claim 9, wherein said excipients are selected from a diluent, a disintegrant, a binder, a solubilizing agent, a lubricant, a sliding agent or a solvent, a desiccant or a combination thereof.
11. Composition as in any claim from 1 to 10, comprising one or more compounds with antioxidant activity.
12. Composition as in claim 11, wherein said one or more compounds with antioxidant activity are selected from: a mixture of antioxidant substances extracted mainly from the bark of Maritime Pine (Pinus pinaster) and/or from the seeds of Vitis vinifera, Lipoic acid, n- Acetyl cysteine, Polyphenols, Resveratrol, Polydatin, Quercetin, Rutin, Luteolin, or a combination thereof.
13. Composition as in claim 11 or 12, wherein said one or more compounds with antioxidant activity are between 5 and 60% w/w of the composition.
14. Composition as in any claim from 1 to 13, wherein said composition is free of terpenes.
15. Composition as in claim 1, wherein said composition comprises CBD and PEA, and it is free of other plant-derived anti-inflammatory and/or pain-relieving substances and/or other active principles or substances, said composition possibly including suitable and pharmaceutically acceptable excipients.
16. Composition as in any claim from 1 to 15, for therapeutic treatment.
17. Composition as in any claim from 1 to 16, for the therapeutic treatment of painful and/or inflammatory states.
18. Composition as in any claim from 1 to 17, for the treatment of somatic pain.
19. Composition as in any claim from 1 to 18, for the treatment of visceral pain.
20. Composition as in any claim from 1 to 19, for the treatment of nonnociceptive pain.
21. Composition as in any claim from 1 to 20, for the treatment of neuropathic pain.
22. Composition as in any claim from 1 to 21, for the treatment of sympathetic pain.
EP22705910.2A 2021-01-28 2022-01-28 Composition for the treatment of painful and/or inflammatory states Pending EP4284351A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT202100001724 2021-01-28
IT202100008447 2021-04-06
PCT/IT2022/050010 WO2022162711A1 (en) 2021-01-28 2022-01-28 Composition for the treatment of painful and/or inflammatory states

Publications (1)

Publication Number Publication Date
EP4284351A1 true EP4284351A1 (en) 2023-12-06

Family

ID=80446974

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22705910.2A Pending EP4284351A1 (en) 2021-01-28 2022-01-28 Composition for the treatment of painful and/or inflammatory states

Country Status (2)

Country Link
EP (1) EP4284351A1 (en)
WO (1) WO2022162711A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023046730A1 (en) * 2021-09-22 2023-03-30 Bionorica Se Cosmetic compositions containing cannabidiol and zingiber extract
WO2023233185A1 (en) * 2022-06-01 2023-12-07 VOLPI, Simone Combination of cannabidiol and alpha-lipoic acid for use in the treatment of ptsd
EP4353225A1 (en) * 2022-10-12 2024-04-17 Erbozeta S.p.A. Nutraceutical or pharmaceutical composition for the treatment of pelvic pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3417846A1 (en) * 2017-06-19 2018-12-26 Gifar Srl Food and/or nutraceutical composition
CA3096062A1 (en) * 2018-04-03 2019-10-10 Pure Green, Llc Tablet or composition having n-acyl ethanolamine and cannabinoid
US10512615B1 (en) * 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
IL272253A (en) * 2020-01-26 2021-07-29 Landver Guy Compositions and methods for treatment of inflammatory conditions and diseases of the skin

Also Published As

Publication number Publication date
WO2022162711A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
WO2022162711A1 (en) Composition for the treatment of painful and/or inflammatory states
Razavi et al. A review of therapeutic potentials of turmeric (Curcuma longa) and its active constituent, curcumin, on inflammatory disorders, pain, and their related patents
KR20200106049A (en) Oral pharmaceutical formulation containing cannabinoids and poloxamers
KR102350519B1 (en) Compositions containing extracts of Curcuma longa and Echinacea angustifolia which are useful to reduce peripheral inflammation and pain
Hügel et al. Danshen diversity defeating dementia
US10953068B2 (en) Anti-inflammatory composition for the treatment of acute joint inflammation and a process for preparation thereof
EP2852379A1 (en) Novel highly bioavailable, water soluble and sustained release nanoformulations of hydrophobic plant derived compounds and extracts
Bharate et al. Discovery and preclinical development of IIIM-160, a Bergenia ciliata-based anti-inflammatory and anti-arthritic botanical drug candidate
Elnour et al. Study of antioxidant and anti-inflammatory crude methanol extract and fractions of Acacia seyal gum
BR112020027097A2 (en) COMBINATION COMPOSITIONS OF CANABIDIOL
Mohammed et al. Assessment of the possible protective effect of sugarcane (Saccharum officinarum) peels extract for experimentally induced hepatotoxicity and renal disorders of adult male Sprague Dawley rats.
Yuan et al. Anti-arthritic and cartilage damage prevention via regulation of Nrf2/HO-1 signaling by glabridin on osteoarthritis
Al-Baroudi et al. Hepatoprotective effect of chamomile capitula extract against 2, 4-dichlorophenoxyacetic acid-induced hepatotoxicity in rats
Anuj et al. Eugenol: A potential phytochemical with multifaceted therapeutic activities
EP3795146B1 (en) Pain-relieving and anti-inflammatory composition for local use
Rajamani et al. Naringenin-loaded TPGS polymeric nanosuspension: In-vitro and in-vivo anti-inflammatory activity
YAŞAR et al. Effect of My Guard® Food Supplement on Acute and Subacute Toxicity on Rats
Mythilypriya et al. Synergistic effect of Kalpaamruthaa on antiarthritic and antiinflammatory properties—its mechanism of action
Hosni et al. Common applications of black cumin Seed (Nigella sativa) oil in folk medicine
BR112021000223A2 (en) formulations containing lipophilic extracts of spicy edible plants useful in the control of pain and inflammation
Ibrahim et al. Curcumin A potential antagonist against paracetamol induced nephrotoxicity in rats.
Maghmomeh THERAPEUTIC EFFECT OF THE CURCUMIN IN CISPLATIN-INDUCED KIDNEY FIBROSIS EXPERIMENTALLY IN RATS
WO2023148668A1 (en) A phytochemical formulation for the treatment of joint inflammation
CN108697751B (en) Composition for preventing and/or treating inflammation and pain
Farooqui et al. Metabolism, bioavailability, biochemical effects of curcumin in visceral organs and the Brain

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240301

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)